MDR1 gene expression in primary and advanced breast cancer

Xiaowei Yang, Beatrice Uziely, Susan Groshen, Jason Lukas, Valerie Israel, Christy Russell, Gary Dunnington, Silvia Formenti, Franco Muggia, Michael F. Press

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

P-glycoprotein (Pgp)-associated multidrug resistance (MDR) is related to intrinsic and acquired cross resistance to anthracyclines, vinca alkaloids, and other antineoplastic antibiotics. Expression of MDR1 is widely considered to play an important role in conferring resistance to adjuvant chemotherapy in women with breast tumor cells in women with disseminated disease, although data supporting this view is, at best, conflicting. The expression of MDR1 gene and its gene product, P-glycoprotein, was investigated in primary and advanced breast cancers (both previously untreated and previously treated on specific treatment protocols) to assess the role of P-glycoprotein in determining responsiveness to adjuvant chemotherapy. Expression was assessed by immunohistochemistry, reverse transcription-PCR (RT-PCR), Northern Blot and Western Blot. MDR1 mRNA was detected in 40% of the breast cancers tested by RT-PCR with 40 cycles of PCR amplification. When reducing the PCR amplification cycles to 28, the MDR1 gene expression signal disappeared from breast cancers of the highest expressers; however, known MDR1 positive control normal tissues, such as adrenal, kidney, and liver continued to show an expression product. Western and Northern blots failed to demonstrate the MDR1 gene product, P-glycoprotein, in these abreast cancers. In contrast, physiologic levels of P-glycoprotein was clearly detected in normal adrenal, kidney, and liver by these techniques. Immunohistochemistry confirmed that breast carcinoma cells lacked P-glycoprotein expression; however, interstitial mononuclear cells, morphologically consistent with lymphocytes or macrophages did show immunostaining in some of these breast tumors. MDR1 gene expression identified by RT-PCR was not correlated either with response to paclitaxel therapy (29 patients able to be evaluated, p = 0.34, Fisher Exact Test) or overall survival (32 breast cancer patients with clinical follow-up information, p = 0.336, log rank). In conclusion, P-glycoprotein was not expressed in breast carcinoma cells at significant levels, although it was expressed in stomal lymphocytes or macrophages. These results suggest that P-glycoprotein does not play a significant role in multidrug resistance of breast cancer.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalLaboratory Investigation
Volume79
Issue number3
StatePublished - Mar 1999
Externally publishedYes

Fingerprint

P-Glycoprotein
Breast Neoplasms
Gene Expression
Polymerase Chain Reaction
Reverse Transcription
Multiple Drug Resistance
Adjuvant Chemotherapy
Northern Blotting
Antineoplastic Antibiotics
Western Blotting
Immunohistochemistry
Macrophages
Lymphocytes
Vinca Alkaloids
Kidney
Liver
Anthracyclines
Clinical Protocols
Paclitaxel
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Yang, X., Uziely, B., Groshen, S., Lukas, J., Israel, V., Russell, C., ... Press, M. F. (1999). MDR1 gene expression in primary and advanced breast cancer. Laboratory Investigation, 79(3), 271-280.

MDR1 gene expression in primary and advanced breast cancer. / Yang, Xiaowei; Uziely, Beatrice; Groshen, Susan; Lukas, Jason; Israel, Valerie; Russell, Christy; Dunnington, Gary; Formenti, Silvia; Muggia, Franco; Press, Michael F.

In: Laboratory Investigation, Vol. 79, No. 3, 03.1999, p. 271-280.

Research output: Contribution to journalArticle

Yang, X, Uziely, B, Groshen, S, Lukas, J, Israel, V, Russell, C, Dunnington, G, Formenti, S, Muggia, F & Press, MF 1999, 'MDR1 gene expression in primary and advanced breast cancer', Laboratory Investigation, vol. 79, no. 3, pp. 271-280.
Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C et al. MDR1 gene expression in primary and advanced breast cancer. Laboratory Investigation. 1999 Mar;79(3):271-280.
Yang, Xiaowei ; Uziely, Beatrice ; Groshen, Susan ; Lukas, Jason ; Israel, Valerie ; Russell, Christy ; Dunnington, Gary ; Formenti, Silvia ; Muggia, Franco ; Press, Michael F. / MDR1 gene expression in primary and advanced breast cancer. In: Laboratory Investigation. 1999 ; Vol. 79, No. 3. pp. 271-280.
@article{107dd68eeb6145e0a2011687bbc93922,
title = "MDR1 gene expression in primary and advanced breast cancer",
abstract = "P-glycoprotein (Pgp)-associated multidrug resistance (MDR) is related to intrinsic and acquired cross resistance to anthracyclines, vinca alkaloids, and other antineoplastic antibiotics. Expression of MDR1 is widely considered to play an important role in conferring resistance to adjuvant chemotherapy in women with breast tumor cells in women with disseminated disease, although data supporting this view is, at best, conflicting. The expression of MDR1 gene and its gene product, P-glycoprotein, was investigated in primary and advanced breast cancers (both previously untreated and previously treated on specific treatment protocols) to assess the role of P-glycoprotein in determining responsiveness to adjuvant chemotherapy. Expression was assessed by immunohistochemistry, reverse transcription-PCR (RT-PCR), Northern Blot and Western Blot. MDR1 mRNA was detected in 40{\%} of the breast cancers tested by RT-PCR with 40 cycles of PCR amplification. When reducing the PCR amplification cycles to 28, the MDR1 gene expression signal disappeared from breast cancers of the highest expressers; however, known MDR1 positive control normal tissues, such as adrenal, kidney, and liver continued to show an expression product. Western and Northern blots failed to demonstrate the MDR1 gene product, P-glycoprotein, in these abreast cancers. In contrast, physiologic levels of P-glycoprotein was clearly detected in normal adrenal, kidney, and liver by these techniques. Immunohistochemistry confirmed that breast carcinoma cells lacked P-glycoprotein expression; however, interstitial mononuclear cells, morphologically consistent with lymphocytes or macrophages did show immunostaining in some of these breast tumors. MDR1 gene expression identified by RT-PCR was not correlated either with response to paclitaxel therapy (29 patients able to be evaluated, p = 0.34, Fisher Exact Test) or overall survival (32 breast cancer patients with clinical follow-up information, p = 0.336, log rank). In conclusion, P-glycoprotein was not expressed in breast carcinoma cells at significant levels, although it was expressed in stomal lymphocytes or macrophages. These results suggest that P-glycoprotein does not play a significant role in multidrug resistance of breast cancer.",
author = "Xiaowei Yang and Beatrice Uziely and Susan Groshen and Jason Lukas and Valerie Israel and Christy Russell and Gary Dunnington and Silvia Formenti and Franco Muggia and Press, {Michael F.}",
year = "1999",
month = "3",
language = "English (US)",
volume = "79",
pages = "271--280",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - MDR1 gene expression in primary and advanced breast cancer

AU - Yang, Xiaowei

AU - Uziely, Beatrice

AU - Groshen, Susan

AU - Lukas, Jason

AU - Israel, Valerie

AU - Russell, Christy

AU - Dunnington, Gary

AU - Formenti, Silvia

AU - Muggia, Franco

AU - Press, Michael F.

PY - 1999/3

Y1 - 1999/3

N2 - P-glycoprotein (Pgp)-associated multidrug resistance (MDR) is related to intrinsic and acquired cross resistance to anthracyclines, vinca alkaloids, and other antineoplastic antibiotics. Expression of MDR1 is widely considered to play an important role in conferring resistance to adjuvant chemotherapy in women with breast tumor cells in women with disseminated disease, although data supporting this view is, at best, conflicting. The expression of MDR1 gene and its gene product, P-glycoprotein, was investigated in primary and advanced breast cancers (both previously untreated and previously treated on specific treatment protocols) to assess the role of P-glycoprotein in determining responsiveness to adjuvant chemotherapy. Expression was assessed by immunohistochemistry, reverse transcription-PCR (RT-PCR), Northern Blot and Western Blot. MDR1 mRNA was detected in 40% of the breast cancers tested by RT-PCR with 40 cycles of PCR amplification. When reducing the PCR amplification cycles to 28, the MDR1 gene expression signal disappeared from breast cancers of the highest expressers; however, known MDR1 positive control normal tissues, such as adrenal, kidney, and liver continued to show an expression product. Western and Northern blots failed to demonstrate the MDR1 gene product, P-glycoprotein, in these abreast cancers. In contrast, physiologic levels of P-glycoprotein was clearly detected in normal adrenal, kidney, and liver by these techniques. Immunohistochemistry confirmed that breast carcinoma cells lacked P-glycoprotein expression; however, interstitial mononuclear cells, morphologically consistent with lymphocytes or macrophages did show immunostaining in some of these breast tumors. MDR1 gene expression identified by RT-PCR was not correlated either with response to paclitaxel therapy (29 patients able to be evaluated, p = 0.34, Fisher Exact Test) or overall survival (32 breast cancer patients with clinical follow-up information, p = 0.336, log rank). In conclusion, P-glycoprotein was not expressed in breast carcinoma cells at significant levels, although it was expressed in stomal lymphocytes or macrophages. These results suggest that P-glycoprotein does not play a significant role in multidrug resistance of breast cancer.

AB - P-glycoprotein (Pgp)-associated multidrug resistance (MDR) is related to intrinsic and acquired cross resistance to anthracyclines, vinca alkaloids, and other antineoplastic antibiotics. Expression of MDR1 is widely considered to play an important role in conferring resistance to adjuvant chemotherapy in women with breast tumor cells in women with disseminated disease, although data supporting this view is, at best, conflicting. The expression of MDR1 gene and its gene product, P-glycoprotein, was investigated in primary and advanced breast cancers (both previously untreated and previously treated on specific treatment protocols) to assess the role of P-glycoprotein in determining responsiveness to adjuvant chemotherapy. Expression was assessed by immunohistochemistry, reverse transcription-PCR (RT-PCR), Northern Blot and Western Blot. MDR1 mRNA was detected in 40% of the breast cancers tested by RT-PCR with 40 cycles of PCR amplification. When reducing the PCR amplification cycles to 28, the MDR1 gene expression signal disappeared from breast cancers of the highest expressers; however, known MDR1 positive control normal tissues, such as adrenal, kidney, and liver continued to show an expression product. Western and Northern blots failed to demonstrate the MDR1 gene product, P-glycoprotein, in these abreast cancers. In contrast, physiologic levels of P-glycoprotein was clearly detected in normal adrenal, kidney, and liver by these techniques. Immunohistochemistry confirmed that breast carcinoma cells lacked P-glycoprotein expression; however, interstitial mononuclear cells, morphologically consistent with lymphocytes or macrophages did show immunostaining in some of these breast tumors. MDR1 gene expression identified by RT-PCR was not correlated either with response to paclitaxel therapy (29 patients able to be evaluated, p = 0.34, Fisher Exact Test) or overall survival (32 breast cancer patients with clinical follow-up information, p = 0.336, log rank). In conclusion, P-glycoprotein was not expressed in breast carcinoma cells at significant levels, although it was expressed in stomal lymphocytes or macrophages. These results suggest that P-glycoprotein does not play a significant role in multidrug resistance of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032919439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032919439&partnerID=8YFLogxK

M3 - Article

C2 - 10092063

AN - SCOPUS:0032919439

VL - 79

SP - 271

EP - 280

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 3

ER -